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Vaccine-Associated Enhanced Respiratory Disease Does Not Interfere
with the Adaptive Immune Response Following Challenge with Pandemic
A/H1N1 2009
Abstract
The implications of sequential prime and challenge with mismatched influenza A viruses is a concern in
mammals, including humans. We evaluated the ability of pigs affected with vaccine-associated enhanced
respiratory disease (VAERD) to generate a humoral immune response against the heterologous challenge
virus inciting the VAERD. Vaccinated and challenged (V/C) pigs were administered an inactivated swine δ-
cluster H1N2 (MN08) vaccine with an HA similar to pre-2009 seasonal human viruses and challenged with
heterologous A(H1N1) pandemic 2009 (H1N1pdm09). Vaccination induced MN08-specific
hemagglutination inhibition (HI) antibody but not cross-reacting H1N1pdm09 HI antibody. However,
vaccinated pigs demonstrated significantly higher post-challenge anti-H1N1pdm09 serum neutralizing (SN)
antibodies at 14 and 21 days post inoculation (dpi) compared to nonvaccinated, challenged pigs (NV/C),
indicating a priming effect of the vaccine. Serum and lung whole virus anti-H1N1pdm09 IgG ELISA
antibodies in the vaccinated group were significantly higher than the challenge only pigs at all-time points
evaluated. Lung IgA ELISA antibodies to both antigens were detected at 2, 5, and 21 dpi in vaccine-primed
pigs, contrasted against mucosal ELISA antibody responses detected only at 21 dpi in the naïve-challenged
group. Collectively, vaccine-primed pigs demonstrated a robust humoral immune response and elevated local
adaptive cytokine levels, indicating VAERD does not adversely affect the induction of an immune response to
challenge with heterologous virus despite the severe clinical disease and underlying lung pathology. Thus,
original antigenic sin does not appear to be a component of VAERD.
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Abstract
The implications of sequential prime and challenge with mismatched influenza A viruses is a concern in mammals,
including humans. We evaluated the ability of pigs affected with vaccine-associated enhanced respiratory disease
(VAERD) to generate a humoral immune response against the heterologous challenge virus inciting the VAERD.
Vaccinated and challenged (V/C) pigs were administered an inactivated swine d-cluster H1N2 (MN08) vaccine
with an HA similar to pre-2009 seasonal human viruses and challenged with heterologous A(H1N1) pandemic
2009 (H1N1pdm09). Vaccination induced MN08-specific hemagglutination inhibition (HI) antibody but not cross-
reacting H1N1pdm09 HI antibody. However, vaccinated pigs demonstrated significantly higher post-challenge
anti-H1N1pdm09 serum neutralizing (SN) antibodies at 14 and 21 days post inoculation (dpi) compared to
nonvaccinated, challenged pigs (NV/C), indicating a priming effect of the vaccine. Serum and lung whole virus
anti-H1N1pdm09 IgG ELISA antibodies in the vaccinated group were significantly higher than the challenge only
pigs at all-time points evaluated. Lung IgA ELISA antibodies to both antigens were detected at 2, 5, and 21dpi in
vaccine-primed pigs, contrasted against mucosal ELISA antibody responses detected only at 21dpi in the naı¨ve-
challenged group. Collectively, vaccine-primed pigs demonstrated a robust humoral immune response and ele-
vated local adaptive cytokine levels, indicating VAERD does not adversely affect the induction of an immune
response to challenge with heterologous virus despite the severe clinical disease and underlying lung pathology.
Thus, original antigenic sin does not appear to be a component of VAERD.
Introduction
Contemporary influenza A viruses (IAV) in NorthAmerican swine are characterized by marked genetic
and antigenic diversity. Current endemic, triple reassortant
IAV’s identified in United States (US) swine have demon-
strated antigenic drift and shift in the hemagglutinin (HA)
gene, resulting in multiple antigenically distinct H1 phylo-
genetic clusters designated a, b, c, and d (43,44). Unlike a, b,
and c cluster viruses that evolved from the classical H1N1
(cH1N1) swine lineage, the d-cluster IAV’s are more geneti-
cally diverse as they contain HA genes similar to human
seasonal H1 viruses (15,44). Continued reassortment has re-
cently been demonstrated between TRIG-containing viruses
and A(H1N1) pandemic 2009 (H1N1pdm09) increasing the
genetic complexity of IAV’s circulating in swine (17,25).
As IAVs have become more genetically diverse in the swine
population, serological cross-reactivity in the hemagglutina-
tion inhibition (HI) assay between H1 phylogenetic clusters
have become more variable (20,41). Inactivated vaccines have
demonstrated limited cross-protection against heterologous
homosubtypic, or heterosubtypic influenza viruses (18,38–
40,42,43). In addition, inactivated vaccines have been associ-
ated with enhanced respiratory disease in swine (7) or po-
tentially increasing the risk of illness in H1N1pdm09-
infected humans who previously received the 2008–09 triva-
lent inactivated influenza vaccine (12,30). We recently
reported a disease phenomenon in swine vaccinated with
monovalent inactivated d-cluster H1N2 vaccine and exposed
to H1N1pdm09, termed vaccine-associated enhanced respi-
ratory disease (VAERD) (7). The mechanism responsible for
VAERD is unknown at this time, although the antibody
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response elicited by inactivated vaccines has been implicated
(7,10,42). A previous report also suggested severe respiratory
disease may have been associated with the immune response
to prior seasonal influenza virus infection or vaccination in
humans infected with H1N1pdm09 (32).
Pigs with VAERD demonstrate severe, prolonged respira-
tory disease and increased macroscopic and microscopic lung
lesions; however, VAERD-affected pigs in experimental set-
tings recover from disease in spite of the negative health im-
pact (7). Due to the widespread use of inactivated vaccines
and the level of reassortment and antigenic drift among IAV’s
in swine, it is increasingly important to understand how prior
vaccine immunity may affect the immune response to the
heterologous challenge virus that incited VAERD and if
original antigenic sin is associated with VAERD.
Materials and Methods
Experimental design, vaccine and virus inoculum
Ninety-one 3-week-old cross-bred pigs of mixed sex were
obtained from a herd free of IAV and porcine reproductive
and respiratory syndrome virus (PRRSV). Upon arrival, pigs
were treated prophylactically with ceftiofur (Pfizer Animal
Health, New York, NY) according to label directions to re-
duce potential respiratory bacterial pathogens and were
housed in biosafety level 2 (BSL2) containment during the
vaccine phase of the study, and at ABSL3 containment for
the challenge phase as previously described (6). Pigs were
cared for in compliance with the Institutional Animal Care
and Use Committee of the National Animal Disease Center.
The experimental design is described in Table 1.
Whole influenza A virus vaccine was prepared with A/
Sw/MN/02011/2008 (MN08) d1 cluster H1N2 at approxi-
mately 32 HA units or 105.7 50% tissue culture infectious dose
(TCID50) per mL and mixed with adjuvant as previously
described (7). Pigs were vaccinated with 2mL by the intra-
muscular route at approximately 6 and 9 weeks of age, and
challenged by the intratracheal route at 13 weeks of age with
2mL of 1· 105 TCID50 of pandemic A/CA/04/2009 H1N1
(H1N1pdm09) as described previously (6). Pigs were hu-
manely euthanized with a lethal dose of pentobarbital
(Sleepaway, Fort Dodge Animal Health, Fort Dodge, IA) on
0, 1, 2, 5, or 21 days post infection (dpi) to evaluate lung
lesions, viral replication. and innate cytokine concentrations
as previously described (6), and the post-challenge humoral
immune and adaptive cytokine responses reported here. Serum
was collected from four pigs in each group at 0, 7, 14, and
21dpi. Postmortem samples included serum (12 pigs) and
bronchoalveolar lavage fluid (BALF) (91 pigs) for this study.
Diagnostic microbiology
All pigs were screened for antibody against influenza A
NP by ELISA (MultiS ELISA, IDEXX, Westbrook, Maine)
upon arrival to ensure absence of preexisting immunity from
prior exposure or maternally derived antibody. BALF samples
from 1, 2, 5, and 21 dpi were cultured for aerobic bacteria on
blood agar and Casmin (NAD enriched) plates. Polymerase
chain reaction (PCR) assays for PCV2 (26), Mycoplasma
hyopneumoniae (31) and RT-PCR for PRRSV were conducted
on nucleic acid extracts from BALF collected at each nec-
ropsy.
Antibody detection assays
Hemagglutination inhibition assays were conducted on
serum from twelve pigs (4 per group) at 0, 7, 14, and 21dpi
with MN08 or H1N1pdm09 virus as antigen and turkey
RBCs as indicators using standard techniques as previously
described (42). Reciprocal titers were divided by 10 and log2
transformed, analyzed, and reported as the geometric mean.
Enzyme-linked immunosorbent assays (ELISA) to detect
total IgG and IgA antibodies against whole virus prepara-
tions of MN08 and H1N1pdm09 present in serum from 12
pigs (4 per group) at 0, 7, 14, and 21dpi, and BALF from 91
pigs (Table 1) at 0, 1, 2, 5, and 21 dpi were performed as
previously described with modifications (7). Sera were heat
inactivated at 56C for 30min and diluted in 5% Fraction V
bovine serum albumin (BSA) (Life Technologies/Gibco,
Grand Island, NY) in phosphate-buffered saline (PBS) at
1:2000 and 1:4 for IgG and IgA assays, respectively, to adsorb
nonspecific binding. The BALF samples were incubated at
37C for 1 h with an equal volume of 10mM dithiothreitol
(DTT) to disrupt mucus prior to dilution with an equal vol-
ume of 10% BSA-PBS resulting in a final BALF dilution of
1:4. The BSA-treated sera and BALF were incubated at 37C
for 1 h immediately prior to testing.
Concentrated MN08 and H1N1pdm09 were resuspended
in Tris-EDTA basic buffer, pH 7.8, and diluted to an HA
concentration of 100 HA units/50 lL. Immulon-2HB 96-well
plates (Dynex, Chantilly, VA) were coated with 50lL of ei-
ther antigen and incubated at room temperature overnight.
Plates were blocked for 1 h at room temperature with 150lL
of Starting Block (Thermo Fisher Scientific, Pittsburgh, PA)
and washed 3 times with 0.05% Tween 20 in PBS (PBS-T).
The assays were performed with 50 lL of diluted sera
or BALF in duplicate. Plates were incubated at room tem-
perature for 1 h, washed 3 times with PBS-T, then incu-
bated with peroxidase-labeled goat anti-swine IgG
(Kirkegaard & Perry Laboratories, Gaithersburg, MD) or IgA
Table 1. Experimental Design and Sample Collection
Group Vaccine Challenge
Serum Samples (N) BALF Samples (N)
0 dpi 7 dpi 14 dpi 21 dpi 0 dpi 1 dpi 2 dpi 5 dpi 21 dpi
V/C MN08 H1N1pdm09 4 4 4 4 4 8 8 8 4
NV/C None H1N1pdm09 4 4 4 4 0 8 8 8 4
NV/NC None None 4 4 4 4 3 8 8 8 4
BALF, bronchoalveolar lavage fluid; dpi, days post inoculation; H1N1pdm09, pandemic A/CA/04/2009 H1N1; MN08, swine d-cluster A/
Sw/MN/02011/2008 inactivated vaccine; NV/C, nonvaccinated/challenged; NV/NC, nonvaccinated/nonchallenged; V/C, vaccinated/
challenged.
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(Bethyl, Montgomery, TX) diluted 1:1,500 in Starting Block for
1 h at room temperature. Plates were washed 3 times with
PBS-T; then 50lL of 2, 2¢-azino-di(3-ethylbenzthiazoline-
6-sulfonate) (ABTS)-peroxide was added as the substrate
(Kirkegaard & Perry Laboratories) for 8–10min prior to add-
ing 50lL KPL Stop Solution (Kirkegaard & Perry Labora-
tories). The optical density (OD) was measured at 405nm
wavelength with an automated ELISA reader. Antibody levels
were reported as the mean OD for each duplicate sample, and
the mean OD of each treatment group was compared.
Serum neutralization (SN) assays were conducted on se-
rum from 12 pigs (4 per group) at 0, 7, 14, and 21dpi as
previously described (7,43). Titers were recorded as the
highest dilution negative for virus staining or CPE after the
presence of virus was verified by immunocytochemistry for
all plates. Reciprocal titers were divided by 10, log2 trans-
formed, analyzed, and reported as the geometric mean.
Cytokine assays
A 5mL aliquot of BALF collected from pigs at 0, 1, 2, 5,
and 21 dpi was centrifuged at 400 · g for 15min at 4C to
pellet cellular debris. Cytokine concentrations in BALF,
which included IL-2, IL-4, IL-12p70, IL-10, and IFN-c, were
determined by multiplex ELISA performed according to the
manufacturer’s recommendations (SearchLight, Aushon
Biosystems, Billerica, MA). Cytokine concentrations were
reported as the mean of duplicate samples for statistical
analysis.
Statistical analysis
Log2 transformed HI and SN reciprocal titers, mean OD
ELISA IgG and IgA antibody levels and cytokine concen-
trations were analyzed using analysis of variance (ANOVA)
with a p value £ 0.05 considered significant ( JMP, SAS In-
stitute, Cary, NC; GraphPad Prism Version 5.00, San Diego,
CA). Response variables shown to have a significant effect by
treatment group were subjected to pair-wise comparisons
using the Tukey–Kramer test.
Results
Viral and microbiological assays
Prior to vaccination, all pigs were free of influenza A NP
specific antibodies and at 5 dpi, all pigs were negative for
PRRSV, PCV2, or M. hyopneumoniae nucleic acids in BALF.
Bacterial pathogens were not detected in the lung with the
exception of Bordetella bronchiseptica in the BALF of one NV/
C pig. Macroscopic and microscopic lung lesions indicative
of VAERD were present in all V/C pigs (VAERD group)
reported previously with nasal shedding and lung virus
titers (6).
VAERD did not prevent induction of HI or SN antibody
responses to heterologous challenge
To evaluate the effect of VAERD on the induction of
H1N1pdm09 specific HI or SN antibody responses, V/C
pre- and post-challenge titers were compared to the naı¨ve-
challenged group (NV/C) (Table 2). Anti-MN08 or
-H1N1pdm09 HI antibodies were not detected in pigs that
did not receive vaccine or challenge virus, respectively,
during the pre- and/or post-challenge phase of the study.
The geometric mean anti-MN08 HI antibody titer in the
VAERD group was significantly higher ( p£ 0.05) than the
NV/C and nonvaccinated/nonchallenged (NV/NC) group
titers at 7, 14, and 21 dpi. Challenge with H1N1pdm09
boosted the mean anti-MN08 HI antibody titer in the V/C
pigs, peaking at 14 dpi. However, post-challenge anti-
H1N1pdm09 HI antibodies did not cross-react with MN08
antigen in nonvaccinated pigs at any time point. This is
consistent with the lack of HI cross-reactivity previously
demonstrated between the vaccine and challenge viruses and
consistent with the VAERD model (41).
Importantly, the vaccine-primed, VAERD-affected group
demonstrated a humoral immune response to the
H1N1pdm09 challenge virus in spite of the severe underly-
ing pathology described previously (6). Moreover, the geo-
metric mean V/C anti-H1N1pdm09 HI antibody titers were
significantly higher ( p £ 0.05) than the NV/C and NV/NC
group at 7 dpi and demonstrated elevated anti-H1N1pdm09
HI titers at 14 and 21dpi compared to the naı¨ve challenged
pigs.
Anti-MN08 or -H1N1pdm09 SN antibodies were not de-
tected in pigs that did not receive vaccine or challenge virus,
respectively, during the pre- and/or post-challenge phase of
the study (Table 3). The VAERD-affected group geometric
mean anti-MN08 SN antibody titers were boosted post-
challenge with H1N1pdm09, peaked earlier at 7 dpi com-
pared to the anti-MN08 HI titer and declined thereafter. In
addition, naı¨ve-challenged pigs did not demonstrate cross-
reactive neutralizing antibodies to MN08 in the absence of
vaccination.
The geometric mean anti-H1N1pdm09 SN antibody titers
in the VAERD-affected group was similar to the primary
immune response demonstrated in the NV/C group at 7 dpi
but were significantly higher ( p£ 0.001) than the NV/C and
NV/NC groups at 14 and 21 dpi. These data suggest VAERD
does not preclude the HI or SN immune response to the
heterologous virus inciting the enhanced disease.
Serum and lung IgG whole virus anti-MN08
and cross-reactive anti-H1N1pdm09 antibody
responses in VAERD-affected pigs
Pre- and post-challenge serum was evaluated for the
presence of cross-reactive, whole virus IgG antibodies in-
duced by the MN08 inactivated vaccine (Table 4). Anti-MN08
and cross-reactive anti-H1N1pdm09 systemic IgG antibodies
were detected in the V/C group prior to challenge at 0dpi,
suggesting the presence of conserved, although nonprotective,
epitopes between vaccine and challenge viruses. Group mean
pre- and post-challenge anti-MN08 and -H1N1pdm09 OD
levels were significantly higher ( p£ 0.001) in vaccine-primed
pigs compared to NV/C and NV/NC pigs at all dpi measured
and demonstrated an increasing trend in post-challenge OD
levels. The NV/C group demonstrated anti-H1N1pdm09 and
cross-reactive anti-MN08 post-challenge IgG OD levels that
were significantly higher ( p£ 0.05) than the NV/NC pigs at 14
and 21dpi, indicating a primary immune response to the
challenge virus that was also cross-reactive against the vaccine
antigen.
Lung lavage fluid was evaluated to assess the level of
vaccine-induced, pre- and post-challenge whole virus mucosal
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IgG antibodies in VAERD-affected pigs (Table 4). IgG anti-
bodies against MN08 and H1N1pdm09 were detected at
significantly higher ( p£ 0.05) levels in the lungs from vaccine-
primed pigs prior to challenge and at 1, 2, 5, and 21dpi com-
pared to NV/C and NV/NC groups. Nonprimed, challenged
pigs demonstrated anti-H1N1pdm09 and cross-reactive anti-
MN08 BALF IgG antibody levels that were significantly higher
( p£ 0.001) than the NV/NC group only at 21dpi, a delay
compared to serum IgG responses. These data suggest
vaccine-induced, cross-reactive whole virus antibodies against
H1N1pdm09 were present at the time of challenge in VAERD-
affected pigs. Challenge with H1N1pdm09 boosted IgG levels
immediately post-challenge (1dpi), suggesting transudation of
antibodies into the lung at the site of infection.
Serum and lung IgA whole virus anti-MN08
and cross-reactive anti-H1N1pdm09 antibody
responses in VAERD-affected pigs
Serum IgA levels specific for MN08 vaccine antigen and
challenge H1N1pdm09 virus were evaluated pre- and post-
inoculation in VAERD-affected pigs (Table 5). Challenge
with H1N1pdm09 did not induce a detectable serum IgA
antibody response to either antigen regardless of prior vac-
cine priming. In addition, the MN08 inactivated vaccine did
not prime for detectable levels of local IgA in the lower re-
spiratory tract, as anti-MN08 IgA mucosal antibodies were
not significantly different in the V/C group at 0 or 1 dpi
compared to the NV/NC pigs. However, at 2 and 5dpi, the
anti-MN08 and -H1N1pdm09 group mean IgA antibody
levels in the lungs of vaccine-primed pigs were significantly
higher ( p£ 0.05) than the NV/C and NV/NC groups, sug-
gesting the inactivated vaccine administered intramuscularly
primed for a more rapid local immune response to challenge.
In contrast, 21 dpi anti-MN08 and -H1N1pdm09 group mean
V/C and NV/C OD levels were similar and significantly
higher ( p£ 0.0001) than the NV/NC group, suggesting a
primary IgA response to the H1N1pdm09 challenge virus in
NV/C pigs. This indicates mucosal challenge with live virus
stimulated a cross-reactive IgA immune response, in contrast
to the undetectable IgA antibodies induced by the in-
activated vaccine.
Post-challenge local adaptive cytokine responses
are increased in VAERD affected pigs
Cytokine protein concentrations in BALF for IL-2, IL-4, IL-
12p70, IFN-c, and IL-10 were measured to evaluate T cell
responses in the lungs of VAERD-affected pigs (Fig. 1). All
cytokines were significantly higher ( p< 0.05) at 5 dpi (nec-
ropsy) in the vaccine-primed pigs who demonstrated
VAERD. Additionally, V/C pigs demonstrated significantly
higher ( p< 0.05) IFN-c levels compared to the other two
groups at 1 and 2dpi, suggesting prior vaccination may have
resulted in the induction of memory T cells as previously
described in MN08-vaccinated pigs and T cell activation
upon challenge (28). However, elevated IL-10 may be a re-
sponse by the host to inhibit pro-inflammatory cytokine
production, IFNc, or natural killer cells that may be con-
tributing to the immunopathology described in VAERD-
affected pigs (6,24). Concentrations of adaptive cytokines in
the V/C pigs returned to baseline levels by 21dpi and no
significant differences were observed between the groups.
Discussion
Genetic mutation and reassortment drives the evolution of
antigenically diverse IAV’s in swine (20–22,44). Genetic di-
versity has been demonstrated in all currently identified H1
Table 2. Hemagglutination Inhibition Geometric Mean Reciprocal Titers – Standard Error of the Mean
in V/C, NV/C, and NV/NC Pigs at 0, 7, 14, and 21DPI
Group
Anti-MN08 HI titers Anti-H1N1pdm09 HI titers
0 dpi 7 dpi 14 dpi 21 dpi 0 dpi 7 dpi 14 dpi 21 dpi
V/C 20.0 – 14.9 a 95.1 – 13.9 a 134.5– 13.9 a 56.6 – 15.6 a 0.0 – 0.0 a 40.0 – 10.0 a 95.1 – 13.9 a 47.6 – 18.1 a
NV/C 0.0 – 0.0 a 0.0 – 0.0 b 0.0 – 0.0 b 0.0 – 0.0 b 0.0 – 0.0 a 20.0 – 13.3 b 67.3 – 11.9 a 23.8 – 13.9 ab
NV/NC 0.0 – 0.0 a 0.0 – 0.0 b 0.0 – 0.0 b 0.0 – 0.0 b 0.0 – 0.0 a 0.0 – 0.0 c 0.0 – 0.0 b 0.0 – 0.0 b
Geometric mean reciprocal HI titers with different letters within a column are significantly different ( p £ 0.05).
dpi, days post inoculation; H1N1pdm09, pandemic A/CA/04/2009 H1N1; MN08, swine d-cluster A/Sw/MN/02011/2008; NV/C,
nonvaccinated/challenged; NV/NC, nonvaccinated/nonchallenged; V/C, vaccinated/challenged.
Table 3. Serum Neutralization Geometric Mean Reciprocal Titers – Standard Error of the Mean in V/C,
NV/C and NV/NC Pigs at 0, 7, 14, and 21DPI
Group
Anti-MN08 SN titers Anti-H1N1pdm09 SN titers
0 dpi 7 dpi 14 dpi 21 dpi 0 dpi 7 dpi 14 dpi 21 dpi
V/C 452.5– 18.2 a 1280.0– 13.3 a 761.1– 19.3 a 640.0– 16.3 a 0.0 – 0.0 a 380.5 – 13.9 a 2152.7 – 15.5 a 1280.0– 13.3 a
NV/C 0.0 – 0.0 b 0.0 – 0.0 b 0.0 – 0.0 b 0.0 – 0.0 b 0.0 – 0.0 a 113.1 – 15.6 a 380.5 – 11.9 b 538.2– 11.9 b
NV/NC 0.0 – 0.0 b 0.0 – 0.0 b 0.0 – 0.0 b 0.0 – 0.0 b 0.0 – 0.0 a 0.0 – 0.0 b 0.0 – 0.0 c 0.0 – 0.0 c
Geometric mean reciprocal SN titers with different letters within a column are significantly different ( p£ 0.05).
dpi, days post inoculation; H1N1pdm09, pandemic A/CA/04/2009 H1N1; MN08, swine d-cluster A/Sw/MN/02011/2008; NV/C,
nonvaccinated/challenged; NV/NC, nonvaccinated/nonchallenged; V/C, vaccinated/challenged.
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phylogenetic clusters (a-, b-, c-, d1, and d2); additionally, the
d-cluster viruses exhibit greater genetic divergence compared
to the other three clusters (20,21,44). Therefore, vaccine-
challenge mismatch is more likely between influenza viruses
derived from the cH1N1 HA lineage and d-cluster viruses.
The objective of the current study was to evaluate if VAERD-
affected pigs establish an adaptive immune response specific
to the heterologous challenge virus, H1N1pdm09, or if
original antigenic sin would predominate. We have previ-
ously demonstrated VAERD using a model where pigs were
vaccinated with an inactivated d1-cluster (human-like) IAV
and challenged with H1N1pdm09 (6,7).
Surviving cohort pigs in the VAERD group developed
anti-H1N1pdm09 HI and SN antibodies in a similar pattern
as the naı¨ve NV/C pigs, suggesting neither antecedent vac-
cine immunity nor VAERD affected the induction of a post-
challenge immune response to heterologous H1N1pdm09.
The VAERD-affected, vaccine-primed pigs challenged with
H1N1pdm09 responded with mildly elevated HI or signifi-
cantly elevated SN titers against H1N1pdm09, suggesting
that priming with inactivated vaccines may result in a more
robust SN antibody response compared to HI antibody lev-
els, regardless of the challenge virus. Conversely, the SN
assay may be more sensitive and able to demonstrate modest
increases in antibody levels undetectable by the HI assay,
implying the SN test may be more sensitive for assessing
functional anti-influenza antibody responses in swine. Serum
neutralization titers have reportedly been higher compared
to HI titers in assays using homologous swine anti-sera and
antigen (35). Previous reports have also demonstrated anti-
influenza SN antibodies in humans that were seronegative
by the HI test further indicating a heightened sensitivity of
SN tests (8).
Anti-MN08 HI and SN antibodies in the V/C group were
boosted post H1N1pdm09 challenge compared to pre-chal-
lenge levels demonstrated at 0 dpi. Priming naı¨ve pigs with
inactivated IAV resulted in a more robust post-challenge
humoral immune response to both the priming antigen and
heterologous challenge virus. This is in spite of the lack of
HI/SN cross-reactivity between vaccine and inoculum
strains prior to secondary exposure and in spite of the dra-
matic lung pathology associated with VAERD. Similar re-
sults were reported in pigs where preexisting HI and SN
immune responses to primary inoculation increased follow-
ing challenge with an antigenically different influenza virus
of the same subtype (35). In that same study, administration
of an inactivated influenza vaccine to pigs previously inoc-
ulated with heterologous virus also boosted preexisting an-
tibody, suggesting this phenomenon may occur regardless of
how the immune system is initially primed (35). In the cur-
rent study, elevated anti-H1N1pdm09 HI and SN titers in the
MN08 vaccine-primed pigs after challenge suggests pigs
may be protected from a subsequent re-exposure to
H1N1pdm09. Detection of post-challenge anti-H1N1pdm09
HI and SN antibodies in the MN08 vaccine-primed pigs in
addition to the boosted antibody levels to the priming MN08
Table 4. Isolate Specific IgG Levels in Serum and BALF Pre- and Post-Challenge with H1N1pdm09
Represented as the Optical Density Value – Standard Error of the Mean in V/C, NV/C, and NV/NC Pigs
Serum IgG Titers BALF IgG Titers
Antigen Group 0 dpi 7 dpi 14 dpi 21 dpi 0 dpi 1 dpi 2 dpi 5 dpi 21 dpi
MN08 V/C 0.82– 0.08 a 0.96– 0.04 a 1.05– 0.02 a 1.10– 0.01 a 0.54– 0.14 a 0.82– 0.09 a 0.77– 0.08 a 1.08– 0.02 a 1.15– 0.00 a
NV/C 0.07– 0.00 b 0.07– 0.00 b 0.33– 0.09 b 0.41– 0.09 b ND 0.03– 0.00 b 0.02– 0.00 b 0.02– 0.00 b 0.79– 0.07 b
NV/NC 0.08– 0.01 b 0.05– 0.00 b 0.10– 0.02 c 0.05– 0.01 c 0.01– 0.00 b 0.02– 0.00 b 0.02– 0.00 b 0.03– 0.00 b 0.02– 0.00 c
H1N1pdm09 V/C 0.54– 0.05 a 0.94– 0.03 a 1.00– 0.03 a 1.10– 0.02 a 0.25– 0.06 a 0.40– 0.07 a 0.37– 0.07 a 0.70– 0.03 a 0.77– 0.01 a
NV/C 0.07– 0.00 b 0.09– 0.00 b 0.43– 0.08 b 0.43– 0.06 b ND 0.03– 0.00 b 0.02– 0.00 b 0.01– 0.00 b 0.54– 0.06 b
NV/NC 0.09– 0.02 b 0.07– 0.02 b 0.13– 0.02 c 0.04– 0.01 c 0.00– 0.00 b 0.01– 0.00 b 0.01– 0.00 b 0.03– 0.00 b 0.01– 0.00 c
Mean OD levels for each antigen with different letters within a column are significantly different ( p£ 0.05).
BALF, bronchoalveolar lavage fluid; dpi, days post inoculation; H1N1pdm09, pandemic A/CA/04/2009 H1N1; MN08, swine d-cluster A/
Sw/MN/02011/2008; ND, not done; NV/C, nonvaccinated/challenged; NV/NC, nonvaccinated/nonchallenged; V/C, vaccinated/
challenged.
Table 5. Isolate Specific IgA Levels in Serum and BALF Pre- and Post-Challenge with H1N1pdm09
Represented as the Optical Density Value – Standard Error of the Mean in V/C, NV/C and NV/NC Pigs
Serum IgA Titers BALF IgA Titers
Antigen Group 0 dpi 7 dpi 14 dpi 21 dpi 0 dpi 1 dpi 2 dpi 5 dpi 21 dpi
MN08 V/C 0.10– 0.00 a 0.18– 0.01 a 0.25– 0.03 a 0.20– 0.03 a 0.03– 0.01 a 0.06– 0.01 a 0.13– 0.05 a 0.48– 0.06 a 1.15– 0.03 a
NV/C 0.13– 0.00 a 0.18– 0.00 a 0.24– 0.02 a 0.18– 0.04 a ND 0.10– 0.04 a 0.02– 0.01 b 0.00– 0.00 b 0.97– 0.09 a
NV/NC 0.10– 0.02 a 0.13– 0.02 a 0.15– 0.02 a 0.13– 0.04 a 0.01– 0.00 a 0.02– 0.01 a 0.00– 0.00 b 0.03– 0.01 b 0.01– 0.01 b
H1N1pdm09 V/C 0.11– 0.00 a 0.17– 0.00 a 0.26– 0.05 a 0.20– 0.04 a 0.01– 0.01 a 0.05– 0.03 a 0.05– 0.01 a 0.16– 0.02 a 0.73– 0.05 a
NV/C 0.12– 0.01 a 0.19– 0.03 a 0.26– 0.03 a 0.17– 0.03 a ND 0.02– 0.01 a 0.02– 0.01 b 0.01– 0.00 b 0.60– 0.06 a
NV/NC 0.12– 0.02 a 0.15– 0.03 a 0.15– 0.03 a 0.14– 0.04 a 0.01– 0.01 a 0.01– 0.00 a 0.00– 0.00 b 0.03– 0.00 b 0.01– 0.01 b
Mean OD levels for each antigen with different letters within a column are significantly different ( p£ 0.05).
BALF, bronchoalveolar lavage fluid; dpi, days post inoculation; H1N1pdm09, pandemic A/CA/04/2009 H1N1; MN08, swine d-cluster A/
Sw/MN/02011/2008; ND, not done; NV/C, nonvaccinated/challenged; NV/NC, nonvaccinated/nonchallenged; V/C, vaccinated/
challenged.
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vaccine antigen does not fit the concept of original antigenic
sin where antibodies exclusive to the priming antigen are
augmented at the expense of a response to unique epitopes
presented by the challenge virus (4,5,9). As the two viruses
evaluated in this study are both of the H1 subtype and
demonstrate non-neutralizing antibody cross-reactivity, they
may be too similar to induce original antigenic sin or it is
possible inactivated vaccines are less prone to induce the
phenomenon (16).
In contrast to the absent cross-reactive anti-H1N1pdm09
HI or SN antibodies in the vaccine-primed pigs prior to
challenge, whole virus cross-reacting anti-H1N1pdm09 IgG
ELISA antibodies were detected in serum and BALF in pigs
euthanized at 0 dpi in the V/C pigs. This suggests cross-
reactive lung IgG antibodies were likely present at the time
of challenge. However, the increase between 0 and 5 dpi
also suggests a rapid post-challenge transudation across
pulmonary capillaries from systemic IgG in the V/C pigs.
The vaccine-induced anti-H1N1pdm09 systemic or mucosal
IgG antibodies were not cross-protective as confirmed by
the presence of infectious virus in the lungs and nasal
swabs of V/C pigs from this study described previously (6)
and in an additional study (7). Although plausible, it re-
mains unknown if these cross-reacting IgG antibodies
contributed to the enhanced pneumonia described in
VAERD (7).
Unlike the anti-MN08 and -H1N1pdm09 IgG antibodies
detected in the lungs of V/C pigs, the inactivated vaccine did
not induce a measureable IgA antibody response to either
antigen by our methods prior to challenge. Consistent with
previous reports, inactivated influenza vaccines adminis-
tered intramuscularly to swine induce lower levels of mu-
cosal IgA compared to live inoculation or intranasal
vaccination with live attenuated influenza vaccines (LAIV),
suggesting mucosal immunization is required for adequate
production of IgA antibody secreting cells to protect the
upper respiratory tract (11,19,27,45). In contrast, live expo-
sure or mucosal vaccination induced cross-reactive IgA,
since challenge with H1N1pdm09 induced a cross-reactive
anti-MN08 IgG and IgA response in the lungs of NV/C pigs
at 21 dpi. Although likely, it is unknown if the anti-MN08
IgA response detected in the lungs of NV/C pigs in this
study is predictive of cross-protection against subsequent
infection with the same or other heterologous IAV without
further study.
Influenza A virus-induced pro-inflammatory cytokine re-
sponses in swine have been extensively studied and shown
to be correlated with viral replication, disease, and lung
pathology (1,7,13,14,33,34,36,37). In addition, elevated pro-
inflammatory cytokines associated with the innate immune
system have been associated with the VAERD phenomenon
(6,7). In contrast, adaptive cytokine responses to influenza
infection in swine have been less frequently reported. The
adaptive cytokines are important in the activation of lym-
phocytes and cells of the innate immune system, prolifera-
tion of T and B cells, cell differentiation, and immune
regulation (29). The V/C pigs in the current study demon-
strated significantly elevated levels of IL-2, IL-4, IL-12p70,
IFN-c, and IL-10 protein in the lung at 5 dpi compared to the
NV/C and NV/NC groups. Most notable was the increased
IL-2 and significantly elevated IFN-c concentrations at 24
and 48 hours post infection in the MN08 vaccine-primed
pigs. This cytokine profile suggests T cell priming in the
immunized pigs, and is consistent with the presence of IL-2
and IFN-c secreting CD4 +CD8 + memory T cells in swine (3)
and with the rapid increase in total antibody against the
heterologous challenge virus in the vaccine primed pigs. An
influenza-specific, cross-reactive CD4+CD8+ memory T cell
population was detected in MN08 vaccine-primed pigs prior
to challenge and reported previously by our group (28).
In the same study, a significant increase in cross-reactive
CD8+ T-cells was detected by flow cytometry in the V/C
pigs post ex vivo stimulation with H1N1pdm09, suggesting
CD8+ T-cells were primed by the inactivated vaccine (28).
These cytotoxic T-cells may have contributed to the elevated
IFN-c concentrations detected in the V/C post-challenge
BALF (3), but also may be associated with the immunopa-
thology in VAERD. Cellular immune mediators in the lung
FIG. 1. Cytokine protein levels (pg/mL) in bronchoalveolar
lavage fluid of vaccinated and H1N1pdm09-challenged (V/
C), nonvaccinated and H1N1pdm09-challenged (NV/C),
and nonvaccinated and nonchallenged (NV/NC) pigs mea-
sured with multiplex ELISA at 1, 2, 5, and 21 days post
inoculation (dpi). Each symbol represents the cytokine-
specific level of individual pigs. Bars represent the
mean – standard error of the mean. Connecting horizontal lines
are significantly different ( p< 0.05).
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may be responsible for damage to infected tissue as a con-
sequence of viral clearance, as previously reported (2).
However, the previous study evaluated pre-challenge T-cell
responses in the peripheral blood that may demonstrate a
different phenotype than post-challenge T-lymphocytes or
central memory CD4+CD8+ T cells that preferentially
traffic in lymphoid tissues or pulmonary lymph nodes. The
magnitude, quality, timing, and the immune compartment of
the CMI response should be considered in future studies
in assessing the correlates of protection as opposed to the
determinants of VAERD.
Although VAERD-affected pigs were able to respond
immunologically to the heterologous challenge without evi-
dence of original antigenic sin, this priming advantage is not
likely to outweigh the clinical impact of the severe lung pa-
thology associated with decreased growth and potential
losses from secondary infections. Prevention of IAV infection
in swine will continue to rely on the use of vaccines; how-
ever, vaccine efficacy depends on the ability to cross-protect
against antigenically diverse influenza viruses that currently
co-circulate in the U.S. and Canada. Therefore, it is critical to
understand the effectiveness of vaccine immune responses to
heterologous infection and how this response may be im-
proved. There is a real risk of VAERD in swine due to the
use of inactivated vaccines and the potential for mismatch of
the HA and NA in the circulating strains. Increasing evi-
dence has been reported that a similar clinical outcome may
have occurred with some human inactivated vaccine prep-
arations following the emergence of H1N1pdm09 (23,30,32).
The model we describe here would be useful for exploring
the risk of inactivated human vaccines in inducing VAERD
to confirm the epidemiologic links reported in people. Col-
lectively, many aspects of the immune and/or immuno-
pathologic response in VAERD require further investigation
to understand the mechanisms associated with vaccine-
induced exacerbation of disease or the effects VAERD may
have on future infections, either viral or bacterial.
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